Sanofi ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
7.1%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
$5.81next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 30 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Dupixent Global Sales Quarterly15.7BTarget: Sustained double-digit growth and indication expansion through LOE in 2031-2033
New Product Launches Revenue Contribution Quarterly0.1Target: Continued expansion to offset mature portfolio erosion
Watch Items
- Dupixent Loss of Exclusivity (LOE) TimelineTrigger: Approaching 2031-2033 patent cliffAction: Monitor pipeline progression of late-stage immunology assets like amlitelimab
- Opella (Consumer Healthcare) Divestment ExecutionTrigger: Completion of controlling stake transfer to CD&RAction: Track deployment of €10.4 billion proceeds into strategic M&A and R&D
Research as of 2 Sep 2026